The triple Nasdaq deficiency notice signals severe distress — the stock is trading well below $1.00 with a $10M market cap. Monitor for any reverse split announcement or business development that could lift the share price. The 180-day cure period provides some time, but without a catalyst (revenue, partnership, or financing), delisting risk remains high. Traders should consider the high probability of a reverse split attempt, which historically compresses further in micro-cap biotechs.
Price Chart
Executive Summary
Instinct Bio disclosed receiving three separate Nasdaq deficiency notices on September 9-10, 2026: failure to maintain the minimum market value of listed securities ($50M), minimum market value of publicly held shares ($15M), and minimum bid price ($1.00). The company has 180-day compliance periods (until March 2027) for each, but faces potential delisting if it cannot cure these deficiencies. With a $10M market cap and no disclosed operational revenue or catalyst, the risk of eventual delisting is material and immediate.
Key Facts
- Nasdaq notified Instinct Bio on Sep 9, 2026 that MVLS was below $50M from Jul 28 to Sep 8, 2026 — non-compliant with Rule 5450(b)(2)(A)
- Nasdaq notified on Sep 10, 2026 that MVPHS was below $15M from Jul 29 to Sep 9, 2026 — non-compliant with Rules 5450(b)(2)(C) or 5450(b)(3)(C)
- Nasdaq notified on Sep 10, 2026 that bid price was below $1.00 per share from Jul 29 to Sep 9, 2026 — non-compliant with Rule 5450(a)(1)
- Company has 180 calendar days (until Mar 8-9, 2027) to regain compliance on each requirement
- Failure to cure could result in delisting from Nasdaq, with appeal rights to a hearings panel
- Company may consider transferring to Nasdaq Capital Market as an alternative
Financial Impact
No financial figures reported in filing. Market cap is $10M, well below the $50M MVLS threshold and $15M MVPHS threshold.
Risk Factors
- Delisting from Nasdaq if compliance is not regained by March 2027
- Reverse stock split may be necessary but could further pressure the stock
- No disclosed revenue, pipeline, or financing to support valuation recovery
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-107729 |
| Document: tm2625442d1_6k.htm | 0001104659-26-107729 |
| Document: 0001104659-26-107729-index-headers.html | 0001104659-26-107729 |
| Document: 0001104659-26-107729-index.html | 0001104659-26-107729 |
| Document: 0001104659-26-107729.txt | 0001104659-26-107729 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | 6-K | $0.2300 | awaiting T+20 | — | $0.2007 (−12.74%) |
Oct 1, 2026 26d ago | 6-K | $0.3533 | awaiting T+20 | — | $0.2007 (−43.19%) |
Sep 15, 2026 6w ago | 6-K | $0.3700 $0.3602 | ▲ +2.65% | ▲ +5.63% | $0.2007 (+45.76%) |
Aug 10, 2026 11w ago | 6-K | $0.4019 $0.3863 | ▼ −3.88% | ▼ −2.97% | $0.2007 (−50.06%) |
Jul 30, 2026 12w ago | 6-K | $0.4990 $0.4470 | ▼ −10.42% | ▼ −14.39% | $0.2007 (−59.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers